Drug Profile
Research programme: hepatitis C virus NS3 protein inhibitors - Bristol-Myers Squibb/Celera Genomics
Alternative Names: APC 6336; Hepatitis C virus NS3 protease inhibitors - Bristol-Myers Squibb/Celera GenomicsLatest Information Update: 16 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Celera Genomics Group
- Developer Bristol-Myers Squibb; Celera Group
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 20 Aug 2001 No-Development-Reported for Hepatitis C in USA (Unknown route)
- 21 Sep 1998 Preclinical development for Hepatitis C in USA (Unknown route)